


























TABLE 1

# NEWLY FDA-APPROVED ANTICANCER THERAPEUTICS: AUGUST 1, 2017-JULY 31, 2018

Approved Indication	Generic Name	Trade Name	Formulation
<b>CAR T-cell Therapy</b>			
Certain type of non-Hodgkin lymphoma	axicabtagene ciloleucel	Yescarta	
Certain types of leukemia and non-Hodgkin lymphoma†	tisagenlecleucel	Kymriah	
<b>Cell-cytoskeleton Modifying Agents</b>			
Certain type of non-Hodgkin lymphoma†	brentuximab vedotin	Adcetris	
<b>Cell-signaling Inhibitors</b>			
Certain type of breast cancer	abemaciclib	Verzenio	
Certain type of non-Hodgkin lymphoma	acalabrutinib	Calquence	
Certain type of non-Hodgkin lymphoma	copanlisib	Aliqopa	
Certain type of thyroid cancer†	dabrafenib and trametinib	Tafinlar and Mekinist	 + 
Certain type of melanoma	encorafenib and binimetinib*	Braftovi and Mektovi	 + 
Certain type of blood cancer†	vemurafenib	Zelboraf	
<b>DNA-damaging Agents</b>			
Certain types of leukemia	daunorubicin and cytarabine	Vyxeos	
Certain types of leukemia	inotuzumab ozogamicin	Besponza	
Certain type of leukemia†	gemtuzumab ozogamicin	Mylotarg	
<b>DNA-repair Inhibitors</b>			
Certain breast cancers†	olaparib*	Lynparza	
<b>Epigenome-modifying Agents</b>			
Certain type of leukemia	enasidenib*	Idhifa	
Certain type of leukemia	ivosidenib*	Tibsovo	
<b>Hormones/Antihormones</b>			
Prostate cancer	apalutamide	Erleada	
<b>Immune-checkpoint Inhibitors</b>			
Certain type of lung cancer†	durvalumab	Imfinzi	
Certain types of colorectal† and liver cancer†	nivolumab	Opdivo	
Certain types of colorectal and kidney cancer†	nivolumab and ipilimumab	Opdivo and Yervoy	 + 
Certain types of lymphoma, stomach, and cervical cancer†	pembrolizumab*	Keytruda	
<b>Radiation-emitting Therapeutics</b>			
Certain types of neuroendocrine tumors	lutetium 177 dotatate	Lutathera	
Certain types of adrenal tumors	iobenguane I131	Azedra	

†new cancer type approved 2017-2018

\* requires a companion diagnostic

Where multiple trade names are used, only the most common have been listed